Shots:

• Amgen entered into an agreement with Abilita Bio for the development of therapies utilizing Abilita’s Enabled Membrane Protein (EMP) technology targeting certain integral membrane proteins
• The focus of the agreement is to discover and develop candidates targeting complex membrane proteins
• EMP technology is a drug discovery platform targeting GPCRs- ion channels- and transporters to develop membrane protein target variants in multiple therapy areas

Ref: Abilita Bio | Image: Twitter